CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 617 enrolled
Drug / intervention
Rapastineldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03002077
NCT03002077Phase 3Completed
CompareCT.gov

An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

Naurex, Inc, an affiliate of Allergan plc·interventional·Posted Dec 23, 2016·Updated Jun 22, 2020

In Brief

A Phase 3 clinical trial evaluating Rapastinel for Depressive Disorder, Major. Completed, enrolled 617 participants across 128 sites.

Detailed Summary

This study will evaluate the long-term safety and tolerability of rapastinel as an adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepressive Disorder, Major
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 23, 2016
Enrollment StartFeb 3, 2017
Primary CompletionDec 6, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.5 years ago

Interventions

Rapastineldrug

Rapastinel pre-filled syringes for IV injections.